PACTR201409000848428尚未招募未知
Evaluating a new treatment regimen for patients with multidrug-resistant TB (MDR-TB) - a randomised controlled Phase 3 trial.
university of Cape Town Lung Institute0 个研究点目标入组 256 人开始时间: 2014年7月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 999 Year(s)（—）
- 性别
- Male
入选标准
- •¿Provide written, informed consent prior to all trial-related procedures including HIV testing.
- •¿Male or female, aged 18 years and older.
- •¿Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
- •¿Newly diagnosed culture and/or GeneXpert positive pulmonary TB.
- •¿GeneXpert rifampicin resistance confirmed on an alternative method of susceptibility testing (line probe assay (LPA) or phenotypic DST using a culture isolate or sputum sample.
- •¿Ability to produce an adequate volume of sputum as estimated from a spot assessment (estimated 10 ml or more overnight production).
- •¿Women of non-childbearing potential or using effective methods of birth control.
排除标准
- •¿Previous history of treatment for MDR-TB.
- •¿Having received any drug active against MDR-TB within 3 months or less prior to enrolment.
- •¿Having been on treatment for drug sensitive TB treatment within 3 months or less prior to enrolment.
- •¿Currently on MDR-TB treatment for more than 2 weeks.
- •¿Fluoroquinolone-resistant and/or aminoglycoside-resistant TB detected (pre-XDR and XDR-TB).
- •¿Rifampicin mono-resistance.
- •¿Incompatibility between microbiological and clinic-radiological findings (i.e. where the clinico-radiological findings do not confirm the positive microbiological testing)
- •¿Primarily extra-thoracic TB as judged by the investigator.
- •¿History of allergy to any of the trial IMP/s or related substances.
- •¿Known or suspected, current alcohol or drug abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the participant.
- •¿Significant cardiac arrhythmia requiring medication.
- •¿Having participated in other clinical studies with investigational agents within 8 weeks prior to trial start.
- •¿Participants with specific ECG abnormalities at screening (see full protocol for details)
- •¿Participant who is pregnant, breast-feeding, or planning to conceive a child within 6 months of cessation of treatment.
- •¿Diabetes Mellitus requiring insulin.
- •¿History and/or presence (or evidence) of neuropathy or epilepsy.
- •¿History and/or presence (or evidence) of any haematogical disorder.
- •¿Specific concurrent treatments:
- •-Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP.
- •-Concomitant use of any drug (other than the study drugs) known to prolong QTc interval (see full protocol for details).
- •-Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes (see full protocol for details). Exceptions may be made for participants that have received 3 days or less of one of these drugs or substances, if there has been a wash-out period before administration of IMP equivalent to at least 5 half-lives of that drug or substance.
- •-Use of any therapeutic agents known to alter any major organ function (see full protocol for details).
- •¿Laboratory abnormalities:
- •Participants with specific toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (November 2007) (see full protocol for details).
研究者
相似试验
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
招募中
2 期
The study of therapy to diarrhea symptoms by the bile acid sequestrantsJPRN-jRCTs031180044Misawa Noboru50
招募中
不适用
Evaluation of treatment regimes in patients with cystic fibrosis and pulmonary excerbations (PEx)E84.0Cystic fibrosis with pulmonary manifestationsDRKS00012924Klinik für Pädiatrie m. S. Pneumologie und ImmunologieCampus Rudolf Virchow Klinikum100
进行中（未招募）
1 期
Pilot study to assess the efficacy of treatment with metformin in patients with Hidradenitis suppurativa refractory to standard treatmentHidradenitis suppurativaEUCTR2016-002714-45-ESInstituto de Investigación Sanitaria Fundación Jiménez Díaz
进行中（未招募）
不适用
Evaluation of a treatment regimen for acromegalyAcromegalyEUCTR2010-023674-39-ATÖsterreichisches Akromegalie Register